ESSENCE CS9 TIMI 73b is a phase 3 multicenter, randomized, double-blind, placebo-controlled trial in ~1320 patients to evaluate the safety and efficacy of olezarsen, an antisense oligonucleotide inhibitor of apoC-III production, administered subcutaneously to patients with either moderate hypertriglyceridemia and atherosclerotic cardiovascular disease (established or at increased risk for) or with severe hypertriglyceridemia.
N Engl J Med. 2025 Oct 2;393(13):1279-1291.
MAIN RESULTS PRESENTATION
Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk-the Essence-TIMI 73b trial (Bergmark, ESC 2025)
PUBLICATIONS
Olezarsen in Patients with Hypertriglyceridemia at High Cardiovascular Risk: Rationale and Design of the Essence-TIMI 73b Trial. Am Heart J. 2025 Aug:286:116-124.
Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia. Reply. N Engl J Med. 2026 Jan 1;394(1):99. doi: 10.1056/NEJMc2515639..Â
Like this:
Like Loading...
